Patents by Inventor Neil J. Hayward

Neil J. Hayward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20240059670
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: February 17, 2023
    Publication date: February 22, 2024
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20230270731
    Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
    Type: Application
    Filed: April 19, 2023
    Publication date: August 31, 2023
    Applicant: eXIthera Pharmaceuticals, Inc.
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Philipp Erik Schneggenburger, Matteo Placido Placidi, Wendy Mercer Geil, Gonto Johns, III
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20230218594
    Abstract: Provided herein are methods of treating a subject who has a viral respiratory infection, comprising administering to the subject a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: July 13, 2023
    Inventors: Neil J. Hayward, Charles V. Pollack, Jr, Michael A. Kurz
  • Therapeutic compounds and compositions
    Patent number: 11691962
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: July 4, 2023
    Assignee: EXITHERA PHARMACEUTICALS, INC.
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20220281813
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 8, 2022
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 11198673
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: December 14, 2021
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210361634
    Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Philipp Erik Schneggenburger, Matteo Placido Placidi, Wendy Mercer Geil, Gonto Johns., III
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210261524
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable salts thereof and compositions and methods of use thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 26, 2021
    Inventors: Neil J. HAYWARD, Bertrand L. CHENARD, Yuelian XU, Roberta L. DOROW, Michael E. MATISON, Alexander KOLCHINSKI, Richard FORNICOLA
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210253550
    Abstract: Provided herein are compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and compositions.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 19, 2021
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Roberta L. Dorow, Michael E. Matison, Alexander Kolchinski, Richard Fornicola
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210188812
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward, Zhiyao Teng
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190359567
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 27, 2019
    Publication date: November 28, 2019
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190315711
    Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Inventors: Bertrand L. Chenard, Yuelian Xu, Frans L. Stassen, Neil J. Hayward
  • Therapeutic compounds and compositions
    Patent number: 10259785
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: April 16, 2019
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20180244614
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 30, 2018
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9994521
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 12, 2018
    Assignee: eXIthera Pharmaceuticals, Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • METHODS AND COMPOSITIONS FOR TREATING DISORDERS
    Publication number: 20180133170
    Abstract: Compounds and compositions for treating disorders related to TRPA1 are described herein.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 17, 2018
    Inventors: Manfred Weigele, Jayhong A. Chong, Glenn R. Larsen, Neil J. Hayward, Amy Ripka, Howard Ng, Magdalene M. Moran, Christopher Fanger, Donato Del Camino, Steven P. Adams
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20170037003
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Therapeutic compounds and compositions
    Patent number: 9499532
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 22, 2016
    Assignee: eXIthera Pharmaceuticals Inc.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20150225389
    Abstract: The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 13, 2015
    Applicant: EXITHERA PHARMACEUTICALS INC.
    Inventors: Robert A. Chrusciel, Robert C. Gadwood, Neil J. Hayward, Michael J. Melnick, Manuel A. Navia, Toni J. Poel, Frans L. Stassen, Catherine A. Stewart
  • Modulators of ?-amyloid peptide aggregation comprising D-amino acids
    Patent number: 7175828
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3–5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: February 13, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Mark A. Findeis, Malcolm L. Gefter, Gary F. Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward